Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study.

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study.
Authors: Miauton A; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland. Electronic address: alix.miauton@unisante.ch., Audran R; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland., Besson J; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Maby-El Hajjami H; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland., Karlen M; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Warpelin-Decrausaz L; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland; Research Support Unit, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Sene L; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland., Schaufelberger S; Information Systems and Digital Transformation, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Faivre V; Information Systems and Digital Transformation, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Faouzi M; Biostatistics Unit, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Hartley MA; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Spertini F; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland., Genton B; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland.
Source: EBioMedicine [EBioMedicine] 2024 Jan; Vol. 99, pp. 104922. Date of Electronic Publication: 2023 Dec 20.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3964
DOI:10.1016/j.ebiom.2023.104922